<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539864</url>
  </required_header>
  <id_info>
    <org_study_id>PSC06</org_study_id>
    <nct_id>NCT00539864</nct_id>
  </id_info>
  <brief_title>Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV</brief_title>
  <official_title>Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protein Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protein Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate and compare the safety, reactogenicity,
      immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent
      influenza vaccine (TIV)in healthy adults age 50-64 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Annual influenza epidemics are associated with serious excess morbidity and mortality,
      particularly among the elderly. Licensed trivalent inactivated influenza vaccines (TIVs) have
      been shown to reduce hospitalization and death following influenza in this vulnerable
      population, but their efficacy is lower than that observed in younger, healthy populations.
      In addition, recent studies have questioned the level of effectiveness of TIV in the elderly,
      suggesting that cohort studies have overestimated the benefits of immunization with current
      TIV formulations in this age group. In view of these considerations, it is widely accepted
      that improved and alternative vaccines are needed for control of seasonal and pandemic
      influenza.

      Currently available TIVs are prepared from viruses that are grown in embryonated hens' eggs.
      Alternative substrates for vaccine production are desirable in order to reduce the
      vulnerability of and to expand influenza vaccine supply. Recombinant DNA techniques allow for
      expression of the influenza hemagglutinin (rHA) by baculovirus vectors in insect cell
      cultures. Advantages of this technique include speed of production, absence of egg protein,
      and a highly purified product. Previous studies among healthy younger and older adults have
      confirmed that rHA vaccines are safe, well tolerated and immunogenic at dosages up to nine
      times higher than those contained in TIV. Dose-related increases in serum antibody levels
      after immunization also were observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)</measure>
    <time_frame>Reactogenicity days 0-7 following immunization; other AEs days 0-28 following immunization</time_frame>
    <description>Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion</measure>
    <time_frame>Day 28 following immunization at Day 0</time_frame>
    <description>Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection</measure>
    <time_frame>Day 28 following immunization at Day 0</time_frame>
    <description>Percentage of participants with (HAI titer greater than or equal to 40) at Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>FluBlok</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV (Fluzone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluBlok Influenza Vaccination</intervention_name>
    <description>0.5mL dose for intramuscular injection</description>
    <arm_group_label>FluBlok</arm_group_label>
    <other_name>FluBlok</other_name>
    <other_name>rHA</other_name>
    <other_name>rHA0</other_name>
    <other_name>recombinant hemagglutinin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV (Fluzone) Influenza Vaccination</intervention_name>
    <description>0.5mL dose for intramuscular injection</description>
    <arm_group_label>TIV (Fluzone)</arm_group_label>
    <other_name>Fluzone</other_name>
    <other_name>TIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 50 to 64.

          -  Females should be at least 2 years post-menopausal or sterile or practicing accepted
             form of birth control (including: condom with spermicidal, licensed hormonal
             contraceptive, abstinence, IUD or monogamous relationship with a vasectomized
             partner).

          -  Healthy, as determined by oral temperature &lt;100.0°F, medical history, and medical
             assessment w/ brief physical evaluation by RN (if indicated) based on medical history.

          -  Able to understand and comply with planned study procedures.

          -  Provides written informed consent prior to initiation of any study procedure.

        Exclusion Criteria:

          -  Known allergy to eggs or other vaccine components.

          -  Immunosuppression as a result of an underlying illness or treatment, or used
             anticancer chemotherapy or radiation therapy within the preceding 36 months.

          -  Any malignancy other than localized prostate cancer, diagnosed or treated actively
             during the past 5 years. Exceptions: Subjects with a history of lymphoproliferative
             disorder at any time in their life will be excluded, while subjects with a history of
             localized nonmelanotic skin cancer that has been completely removed during the past 5
             years may be eligible.

          -  Long-term use of oral steroids, parenteral steroids, or high-dose inhaled steroids
             (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6
             months (Nasal and topical steroids are allowed).

          -  Diagnosis of or treatment for bipolar disorder, severe major depression, schizophrenia
             or other major psychotic disorder in the past 3 months that is associated with
             severely impaired judgment or cognition.

          -  History of receiving immunoglobulin or other blood product within the 3 months prior
             to enrollment in this study.

          -  Receipt of any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4
             weeks (for live vaccines) prior to enrollment in this study.

          -  Use of experimental vaccines or any influenza vaccine other than FluBlOk after May
             31st 2007 for the 2008 Southern Hemisphere or 2007 to 2008 Northern hemisphere
             epidemic seasons.

          -  History of severe reactions following immunization with influenza virus vaccines.

          -  Moderate to severe acute illness or febrile illness (oral temperature greater than
             100degreesF) within 1 week prior to vaccination.

          -  Receipt of an experimental agent (vaccine, drug, biologic, device, blood product or
             medication) within 1 month prior to enrollment in this study, or expects to receive an
             experimental agent during study period.

          -  Known active human immunodeficiency virus, hepatitis B, or hepatitis C infection.

          -  History of alcohol or drug abuse in the last 5 years.

          -  History of Guillain-Barré Syndrome.

          -  Subject is not available for three (3) or more consecutive weeks during active
             influenza season.

          -  Any acute or chronic medical condition that, in the opinion of the investigator, would
             render vaccination unsafe, interfere with the evaluation of responses, or render the
             subject unable to meet the requirements of the protocol. These conditions include, but
             are not limited to: history of significant renal impairment (dialysis and treatment
             for kidney disease, including diabetic and hypertensive kidney disease); subjects with
             diabetes mellitus, well-controlled with oral agents may enroll as long there has been
             no dosage increase within the past 6 months; insulin-dependent diabetes is excluded;
             cardiac insufficiency, if heart failure is present (New York Heart Association
             Functional Class III or IV); an arteriosclerotic event during the 6 months prior to
             enrollment (e.g., history of myocardial infarction, stroke, recanalization of femoral
             arteries, or transient ischemic attack)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Baxter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanenter Center for Vaccine Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Pediatric Clinic - Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Pediatric Clinic - Hayward</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Pediatric Clinic - Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Pediatric Clinic - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://proteinsciences.com</url>
  </link>
  <results_reference>
    <citation>Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28.</citation>
    <PMID>21277410</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2007</study_first_posted>
  <results_first_submitted>May 16, 2011</results_first_submitted>
  <results_first_submitted_qc>July 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2011</results_first_posted>
  <last_update_submitted>July 25, 2011</last_update_submitted>
  <last_update_submitted_qc>July 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Manon MJ Cox</name_title>
    <organization>Protein Sciences Corporation</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects 50 - &lt;64 years of age were screened in participating outpatient clinics for eligibility within 30 days of randomization during the 2007 influenza season.</recruitment_details>
      <pre_assignment_details>Subjects whose laboratory values were exclusionary were not randomized. Women of child-bearing potential were required to have a negative pregnancy test.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FluBlok</title>
          <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
        </group>
        <group group_id="P2">
          <title>TIV (Fluzone)</title>
          <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FluBlok</title>
          <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
        </group>
        <group group_id="B2">
          <title>TIV (Fluzone)</title>
          <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="302"/>
            <count group_id="B3" value="602"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="3.71"/>
                    <measurement group_id="B2" value="55.7" spread="3.64"/>
                    <measurement group_id="B3" value="55.8" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.</title>
        <description>Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.</description>
        <time_frame>Day 0 and Day 28</time_frame>
        <population>All randomized subjects who received study vaccine and had Day 0 and Day 28 HAI titers</population>
        <group_list>
          <group group_id="O1">
            <title>FluBlok</title>
            <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
          </group>
          <group group_id="O2">
            <title>TIV (Fluzone)</title>
            <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.</title>
          <description>Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.</description>
          <population>All randomized subjects who received study vaccine and had Day 0 and Day 28 HAI titers</population>
          <units>HAI Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands (H1N1) - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.71" lower_limit="25.59" upper_limit="32.21"/>
                    <measurement group_id="O2" value="27.77" lower_limit="25.07" upper_limit="30.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands (H1N1) - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.34" lower_limit="159.61" upper_limit="206.02"/>
                    <measurement group_id="O2" value="139.74" lower_limit="124.64" upper_limit="156.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin (H3N2) - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.57" lower_limit="16.37" upper_limit="21.06"/>
                    <measurement group_id="O2" value="18.20" lower_limit="16.07" upper_limit="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin (H3N2) - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.41" lower_limit="91.01" upper_limit="122.09"/>
                    <measurement group_id="O2" value="60.88" lower_limit="53.58" upper_limit="69.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.49" lower_limit="43.38" upper_limit="54.19"/>
                    <measurement group_id="O2" value="49.18" lower_limit="43.77" upper_limit="55.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia - Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.93" lower_limit="100.07" upper_limit="122.97"/>
                    <measurement group_id="O2" value="116.03" lower_limit="104.16" upper_limit="129.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)</title>
        <description>Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.</description>
        <time_frame>Reactogenicity days 0-7 following immunization; other AEs days 0-28 following immunization</time_frame>
        <population>Safety population included all randomized subjects who received a dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>FluBlok</title>
            <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
          </group>
          <group group_id="O2">
            <title>TIV (Fluzone)</title>
            <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)</title>
          <description>Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.</description>
          <population>Safety population included all randomized subjects who received a dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion</title>
        <description>Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization</description>
        <time_frame>Day 28 following immunization at Day 0</time_frame>
        <population>All randomized subjects who received study vaccine and who had day 0 and day 28 HAI titers</population>
        <group_list>
          <group group_id="O1">
            <title>FluBlok</title>
            <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
          </group>
          <group group_id="O2">
            <title>TIV (Fluzone)</title>
            <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion</title>
          <description>Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization</description>
          <population>All randomized subjects who received study vaccine and who had day 0 and day 28 HAI titers</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>% of participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="66.8" upper_limit="77.2"/>
                    <measurement group_id="O2" value="66" lower_limit="60.6" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="55.4" upper_limit="66.8"/>
                    <measurement group_id="O2" value="44" lower_limit="38.0" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="35.2" upper_limit="46.6"/>
                    <measurement group_id="O2" value="41" lower_limit="35.5" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection</title>
        <description>Percentage of participants with (HAI titer greater than or equal to 40) at Day 28</description>
        <time_frame>Day 28 following immunization at Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FluBlok</title>
            <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
          </group>
          <group group_id="O2">
            <title>TIV (Fluzone)</title>
            <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection</title>
          <description>Percentage of participants with (HAI titer greater than or equal to 40) at Day 28</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A/Solomon Islands (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93.5" upper_limit="98.1"/>
                    <measurement group_id="O2" value="96" lower_limit="92.8" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A/Wisconsin (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="80.8" upper_limit="89.1"/>
                    <measurement group_id="O2" value="75" lower_limit="69.9" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89.5" upper_limit="95.6"/>
                    <measurement group_id="O2" value="94" lower_limit="91.1" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs - 28 days following immunization; SAEs for duration of influenza season.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FluBlok</title>
          <description>Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
135μg total</description>
        </group>
        <group group_id="E2">
          <title>TIV (Fluzone)</title>
          <description>Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45μg total
(Fluzone, sanofi pasteur)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal Syncope</sub_title>
                <description>Subject experienced a syncopal episode, was treated with intravenous fluids in ER and discharged home without sequelae.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa M. Dunkle, M.D., Chief Medical Officer</name_or_title>
      <organization>Protein Sciences Corporation</organization>
      <phone>203-599-6064 ext 153</phone>
      <email>ldunkle@proteinsciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

